uniQure (NASDAQ:QURE) Releases Earnings Results

uniQure (NASDAQ:QURE) posted its earnings results on Tuesday. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21, Zacks reports. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million.

uniQure Price Performance

Shares of NASDAQ:QURE traded up $0.27 during midday trading on Thursday, hitting $7.43. The company’s stock had a trading volume of 1,363,612 shares, compared to its average volume of 1,414,395. uniQure has a 12-month low of $3.73 and a 12-month high of $11.35. The company has a market cap of $361.84 million, a P/E ratio of -1.27 and a beta of 0.90. The company has a debt-to-equity ratio of 1.06, a quick ratio of 7.36 and a current ratio of 7.36. The business’s 50 day simple moving average is $5.70 and its 200 day simple moving average is $5.79.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. The Goldman Sachs Group lowered their price target on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 target price on shares of uniQure in a research report on Wednesday. Raymond James reissued an “outperform” rating and issued a $20.00 price target on shares of uniQure in a research note on Thursday, October 10th. Royal Bank of Canada reduced their price objective on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, uniQure has a consensus rating of “Hold” and an average price target of $17.00.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.